ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Core Insights - ARS Pharmaceuticals has expanded access to neffy, an epinephrine nasal spray, to approximately half of all patients managing Type 1 allergic reactions by adding it to 30 formularies, including those of Cigna Healthcare, Navitus Health Systems, and OptumRx [1][2][3] Group 1: Product Information - Neffy is the first FDA-approved epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, for patients weighing 30 kg or more [4][7] - The product is designed for rapid administration, is portable, and has a shelf-life of 30 months with temperature stability up to 122 degrees Fahrenheit [4] - A supplemental NDA for neffy 1 mg, aimed at children over four years old weighing 15 to 30 kg, has a target action date of March 6, 2025, with expected availability by the end of May 2025 [5] Group 2: Market Impact - The addition of neffy to formularies improves coverage for approximately 20 million individuals diagnosed with severe Type I allergic reactions who require epinephrine therapy [3][15] - Millions of patients now have improved access to neffy through commercial insurance, with a low copay of $25 available for those insured by OptumRx, Cigna Healthcare, and Navitus Health Systems [2][3] Group 3: Company Commitment - ARS Pharmaceuticals is committed to ensuring continued access to neffy for patients and caregivers, highlighting the critical demand for a nasal spray option in the severe allergy community [2][3] - The company is actively working with UnitedHealthcare to add neffy to their formulary [2]